伍擎

We are proud to introduce our distinguished speaker lineup for the 𝐀𝐃𝐂 𝐀𝐬𝐢𝐚 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝟐𝟎𝟐𝟔 #ADC2026 on 11-12 March 2026 at Sands Expo & Convention Centre, Singapore. Join us to gain unparalleled insights from the pioneers and innovators shaping the technological innovations, clinical developments, and strategic collaborations in ADC advancement. Our confirmed speakers include: • Paul Moore, Chief Scientific Officer, Zymeworks, USA • Bin Zou, Founder and CEO, Axcynsis Therapeutics, Singapore • Simon Shih-Hsien Chuang, CEO, Honeybear Bioscience, Taiwan • Doo Young Jung, CEO, Pinotbio Inc, Korea • Ben Ayers, Vice President, Antibody-Drug Conjugates, Hummingbird Bioscience, Singapore • David Huang, Senior Director, Head of ADC Enabling Technologies, OBI Pharma, Taiwan This is your opportunity to learn from the best and connect with 300+ senior leaders driving ADC innovation. We look forward to seeing you there as we explore the next frontier in biotherapeutics. 🔗 Secure your spot now: [https://hubs.ly/Q03QmyXM0] #ADC2026 #ADCs #AntibodyDrugConjugate #Biotech #Pharma #LifeSciences #Conference #Innovation #SpeakerLineup #AsiaBiotech

#ADC2026 Life Science Conference - Most comprehensive ADC conference dedicated to Asia-Pacific—where decision-makers gather to exchange ideas, celebrate excellence, explore opportunities, and drive business deals | The ADC Asia Congress 2026 will gather 300+ industry leaders in Singapore to explore the latest innovations in ADC development.

13th Edition Life Science Conference - 13 Years of Excellence: Taiwan’s Premier Biologics Summit Driving Innovation Across Manufacturing, R&D & Clinical Trials | Biologics World Taiwan 2026 is the leading platform where over 300 global and local experts converge to shape the future of biologics, spanning Manufacturing, R&D, and Clinical Trials for biologic drugs, vaccines and Cell and Gene Therapies.

Pre-Conference Day Monday, 23rd February Day One Tuesday, 24th February Day Two Wednesday, 25th February Post-Conference Day Thursday, 26th February Introduction to ADCs Day 4th Novel Conjugates Day…

Meet the expert speaker faculty at the Targeted Therapies Asia Summit. See leaders from Novartis, J&J, Pfizer, Roche, and more discussing licensing and R&D.

台灣浩鼎生技（4174.TWO，以下簡稱「浩鼎」）今日（09/03）宣布，已與圓祥生技（6945.TWO，以下 […]

# ADC bioprocessing In the last 14 days, #WIPO published a patent application (WO2025155626) on a manufacturing process and purification strategy for two specific antibody-drug conjugates (#ADC): OBI-902 (an anti-TROP2 ADC) and OBI-904 (an anti-Nectin-4 ADC). 💡 The manufacturing of ADCs involves several challenges: 1️⃣ Protein purification: Ensuring the monoclonal antibody is of high purity before conjugation. 2️⃣ Site-specific conjugation: Linking the drug to the antibody in a controlled, reproducible manner to maintain efficacy and minimise heterogeneity. 3️⃣ Drug-to-antibody ratio (DAR): The average number of drug molecules attached to each antibody molecule must be carefully controlled, as it influences pharmacokinetics, efficacy, and toxicity. 4️⃣ Stability and quality: Buffer systems, glycosylation patterns, and aggregation must be monitored to meet regulatory requirements. 💡 Affinity chromatography using Protein A or G is routinely used to purify antibodies by leveraging their Fc-region binding. However, post-conjugation purification—such as hydrophobic interaction chromatography (HIC)—is required to remove unbound drug, aggregates, and other impurities. 💡 This disclosure presents a detailed and refined manufacturing platform for producing clinical-grade anti-TROP2 and anti-Nectin-4 ADCs. By combining well-established purification methods (e.g., Protein A chromatography, HIC) with advanced analytical and buffer optimisation techniques, the inventors have created a reproducible system for producing high-quality ADCs. The emphasis on glycosylation profiling, selective bioconjugation, and post-conjugation purification ensures the structural integrity, efficacy, and safety of the resulting ADCs. ✅ Achieve high purity and batch-to-batch consistency of ADCs ✅ Provide robust analytical frameworks for evaluating ADC quality ✅ Enable formulation of OBI-902 and OBI-904 into clinically suitable pharmaceutical compositions The inventors of this patent are Ming-Tain Lai, JUN HONG Richard CHOU , Wang Shy-Guey , Huang Chen-Ping , Chou Bing-Cheng , Lin Hsiao-Han , Chen Ying-Shan from OBI Pharma. #antibody #DrugDevelopment #patent #intellectualproperty